Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $84, while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ROBO | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $529.65 |
52-Week Low | $62.34 | $376.62 |
Market Cap | — | $132.79B |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO trades at $84.44, up 1.65% with bullish momentum from moving averages and a neutral oscillator stance. Recent news highlights robotics sector strength, with thematic ETFs gaining attention for AI infrastructure exposure. The stock faces resistance near $85, with support at $84.
Outlook remains positive due to AI-driven demand, but overbought RSI signals caution. Risks include cyclical exposure and valuation concerns. Analysts favor long-term growth, yet near-term volatility may test recent gains.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
